Celaid closes Series B with Shionogi, partner as US trials loom

Tokyo-based Celaid Therapeutics has reportedly closed its Series B round with backing from Shionogi & Co. and a corporate venture firm, positioning the company for next steps in its pipeline development.

Sources suggest the latest tranche of the round may have raised approximately $2.6 million, though neither Celaid nor its investors have confirmed details. The addition of Shionogi marks what appears to be the pharma giant’s first publicly disclosed investment in the biotech, though the extent of their collaboration remains unspecified.

Celaid’s lead asset, CLD-001, is said to be approaching a key phase in its development, with indications pointing toward future activity in the US. The timing of the funding comes as early-stage biotechs navigate a cautious market, where strategic partnerships often serve as a proxy for investor confidence. Shionogi’s involvement could hint at broader alignment with Celaid’s therapeutic focus, though neither party has elaborated on potential collaboration terms.

The round’s structure—characterized by tranches and corporate participation—reflects a common approach among biotechs securing capital from partners with both financial and operational interests. The identity of the second investor suggests a possible strategic fit, though their role beyond funding has not been clarified.

What comes next will likely depend on the progress of Celaid’s pipeline. If development milestones are met, the company could see further interest from investors or partners, particularly those looking to engage with Japan’s evolving biotech landscape. For now, the reported close offers a notable development in a funding environment where early-stage biotechs often face challenges securing follow-on capital.

Sources: msn.com